Extending the BEAGLE library to a multi-FPGA platform

MRI-based brain tumor segmentation using FPGA-accelerated neural network

Background

Brain tumor segmentation is a challenging problem in medical image processing and analysis. It is a very time-consuming and error-prone task. In order to reduce the burden on physicians and improve the segmentation accuracy, the computer-aided detection (CAD) systems need to be developed. Due to the powerful feature learning ability of the deep learning technology, many deep learning-based methods have been applied to the brain tumor segmentation CAD systems and achieved satisfactory accuracy. However, deep learning neural networks have high computational complexity, and the brain tumor segmentation process consumes significant time. Therefore, in order to achieve the high segmentation accuracy of brain tumors and obtain the segmentation results efficiently, it is very demanding to speed up the segmentation process of brain tumors.

Results

Compared with traditional computing platforms, the proposed FPGA accelerator has greatly improved the speed and the power consumption. Based on the BraTS19 and BraTS20 dataset, our FPGA-based brain tumor segmentation accelerator is 5.21 and 44.47 times faster than the TITAN V GPU and the Xeon CPU. In addition, by comparing energy efficiency, our design can achieve 11.22 and 82.33 times energy efficiency than GPU and CPU, respectively.

Conclusion

We quantize and retrain the neural network for brain tumor segmentation and merge batch normalization layers to reduce the parameter size and computational complexity. The FPGA-based brain tumor segmentation accelerator is designed to map the quantized neural network model. The accelerator can increase the segmentation speed and reduce the power consumption on the basis of ensuring high accuracy which provides a new direction for the automatic segmentation and remote diagnosis of brain tumors.

Benchmarking 2D/3D/MD-QSAR Models for Imatinib Derivatives: How Far Can We Predict?

Imatinib, a 2-phenylaminopyridine-based BCR-ABL tyrosine kinase inhibitor, is a highly effective drug for treating Chronic Myeloid Leukemia (CML). However, cases of drug resistance are constantly emerging due to various mutations in the ABL kinase domain; thus, it is crucial to identify novel bioactive analogues. Reliable QSAR models and molecular docking protocols have been shown to facilitate the discovery of new compounds from chemical libraries prior to experimental testing. However, as the vast majority of QSAR models strictly relies on 2D descriptors, the rise of 3D descriptors directly computed from molecular dynamics simulations offers new opportunities to potentially augment the reliability of QSAR models. Herein, we employed molecular docking and molecular dynamics on a large series of Imatinib derivatives and developed an ensemble of QSAR models relying on deep neural nets (DNN) and hybrid sets of 2D/3D/MD descriptors in order to predict the binding affinity and inhibition potencies of those compounds. Through rigorous validation tests, we showed that our DNN regression models achieved excellent external prediction performances for the pKi data set (n = 555, R² ≥ 0.71. and MAE ≤ 0.85), and the pIC₅₀ data set (n = 306, R² ≥ 0.54. and MAE ≤ 0.71) with strict validation protocols based on external test sets and 10-fold native and nested cross validations. Interestingly, the best DNN and random forest models performed similarly across all descriptor sets. In fact, for this particular series of compounds, our external test results suggest that incorporating additional 3D protein-ligand binding site fingerprint, descriptors, or even MD time-series descriptors did not significantly improve the overall R² but lowered the MAE of DNN QSAR models. Those augmented models could still help in identifying and understanding the key dynamic protein-ligand interactions to be optimized for further molecular design.